Market Navigator

Name: Inside Edge’s Todd Gordon: Halozyme Therapeutics are beating estimates; raised full-year guidance
Uploaded: 2026-10-15T18:53:53.000Z
Duration: 2 min 43 s
Description: Todd Gordon, Inside Edge Capital founder, joins 'Power Lunch' to discuss why it may be time to rotate out of tech and why he likes Halozyme Therapeutics.

In this video

HALO

Market Navigator

Inside Edge’s Todd Gordon: Halozyme Therapeutics are beating estimates; raised full-year guidance

Todd Gordon, Inside Edge Capital founder, joins 'Power Lunch' to discuss why it may be time to rotate out of tech and why he likes Halozyme Therapeutics.

02:43

Thu, Oct 15 20262:53 PM EDT